Personalized risk screening catches more breast cancers, cuts unnecessary tests

A study of 46,000 women suggests that one-size-fits-all annual mammograms might be doing it backwards. Instead of screening everyone at the same interval, researchers found that tailoring screening frequency to individual risk — based on genetics, age, lifestyle, and family history — catches cancers earlier while sparing lower-risk women from unnecessary testing.

The shift is significant because it moves away from the assumption that age alone determines screening need. "These findings should transform clinical guidelines," said Laura Esserman, director of the UCSF Breast Care Center, who led the study. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors."

Here's how it worked in practice. Researchers in the WISDOM study divided participants into four risk tiers. The 26% of women at lowest risk were told to wait until age 50 or until their risk profile matched that of a typical 50-year-old. The 62% with average risk screened every two years. The 8% with elevated risk got annual mammograms. The 2% at highest risk received two screenings yearly, alternating between mammography and MRI.

The result: no increase in advanced cancers among those screened less frequently. In other words, the lower-risk women weren't being left behind — they were just being screened more efficiently.

What's particularly striking is what happened when women were given the choice. When 89% of participants in an observational group opted for risk-based screening over standard annual testing, it suggested this approach isn't just medically sound — it's what people actually prefer when they understand the trade-offs.

The genetic piece changes the equation

One finding could reshape who gets offered genetic testing. Thirty percent of women who tested positive for genetic risk variants didn't have a family history of breast cancer. Under current guidelines, they'd never have been tested in the first place.

The study didn't just look for well-known high-risk genes like BRCA1 and BRCA2. Researchers also measured polygenic risk scores — smaller DNA variations that, taken together, predict risk more precisely. This approach shifted 12–14% of participants to a different risk category, making the screening algorithm more accurate.

"This is one of the first studies to offer genetic testing to all women, regardless of family history," said Allison Fiscalini, director of the WISDOM study. For women who discover elevated genetic risk, the study also offered personalized prevention strategies — diet and exercise guidance, risk-reducing medications, and direct support from breast health specialists.

The researchers are already moving forward. WISDOM 2.0 is now enrolling participants, with a focus on identifying women at higher risk for more aggressive breast cancers so they can receive screening and prevention tailored to their specific biology.

The broader implication is simple: screening works better when it's built around the person, not the protocol.